Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyDavid S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 1.4k
Mechanisms of receptor tyrosine kinase activation in cancerZhenfang Du, Christine M. Lovly|Molecular Cancer|2018Cited by 1.1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021David S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1k
Non–Small Cell Lung Cancer, Version 4.2024Gregory J. Riely, Lisa Hang, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 746
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyDouglas B. Johnson, Justin M. Balko, Mónica V. Estrada et al.|Nature Communications|2016Cited by 572